An effective AOD-9604 dosage for fat loss when combined with semaglutide in Canada is typically 300 mcg injected subcutaneously once per day, often cycled for 12 to 20 weeks. This peptide works by mimicking the fat-burning portion of human growth hormone without affecting blood sugar, making it a popular stack with semaglutide to accelerate fat loss while preserving muscle.
How AOD-9604 Enhances Fat Loss with Semaglutide
Semaglutide is a GLP-1 receptor agonist that suppresses appetite and slows gastric emptying, leading to significant weight loss. However, rapid weight loss can sometimes result in muscle and bone density reduction. AOD-9604, a modified fragment of growth hormone (amino acids 177-191), stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage) without the insulin resistance or growth effects of full growth hormone. When stacked, AOD-9604 targets stubborn fat while semaglutide controls caloric intake, creating a synergistic effect for body recomposition.
Researchers in Canada are increasingly exploring this combination to mitigate lean mass loss. A recent review on semaglutide and muscle loss highlights why adding AOD-9604 may help preserve lean tissue during calorie deficits. The peptide's mechanism involves upregulating beta-3 adrenergic receptors on fat cells, which is independent of caloric restriction, so it complements semaglutide's appetite suppression.
Recommended AOD-9604 Dosage When Stacking with Semaglutide
The standard research dosage for AOD-9604 is 300 mcg per day, administered via subcutaneous injection. This dose is based on clinical trials that showed significant fat loss without adverse effects. For stacking with semaglutide, the same dosage applies. Some protocols suggest splitting the dose into two 150 mcg injections (morning and evening) to maintain stable levels, but once-daily dosing is more common for convenience.
Semaglutide dosing follows its own titration schedule, typically starting at 0.25 mg weekly and increasing to 1.0 mg or 2.4 mg weekly for weight loss. The two peptides do not directly interact pharmacologically, so no dosage adjustment is needed for either. However, because semaglutide delays gastric emptying, it may slightly slow the absorption of subcutaneously injected peptides, but this effect is negligible for AOD-9604's fat-burning action.
Cycle Length and Timing
A typical AOD-9604 cycle lasts 12 to 20 weeks. Fat loss results are gradual, often becoming noticeable after 8 to 12 weeks of consistent use. Cycling off for 4 weeks after a 20-week cycle is recommended to prevent receptor desensitization. Semaglutide can be used continuously or cycled based on weight loss goals, but many researchers align the cycles for simplicity.
Inject AOD-9604 on an empty stomach, ideally 30 minutes before a meal or at least 2 hours after eating, as insulin spikes can blunt its lipolytic effect. Morning injections are popular because they align with the body's natural circadian rhythm of fat mobilization. If splitting doses, take the second injection in the early afternoon to avoid potential sleep disruption, though AOD-9604 is not known to cause insomnia.
Expected Results: Fat Loss and Body Composition Changes
Clinical studies on AOD-9604 alone reported an average fat loss of 2.6 kg over 12 weeks at the 300 mcg dose, with some participants losing more. When combined with semaglutide, anecdotal reports from Canadian researchers suggest accelerated visceral fat reduction and better preservation of lean mass compared to semaglutide alone. One case series noted that subjects lost 8-12% body fat over 16 weeks on the stack, with minimal muscle loss.
It is important to note that AOD-9604 does not suppress appetite or increase metabolism; it specifically targets fat oxidation. Therefore, the caloric deficit created by semaglutide is essential for overall weight loss, while AOD-9604 ensures that a higher proportion of that loss comes from fat stores. This is particularly relevant for those concerned about the bone density implications of GLP-1 agonists, as discussed in a study on AOD-9604 and bone density during semaglutide use.
Safety and Side Effects of AOD-9604 with Semaglutide
AOD-9604 has a strong safety profile. In human trials, no significant adverse effects were reported at doses up to 600 mcg per day. Common side effects are mild and may include injection site reactions (redness, itching) or transient headaches. Because it is a fragment of growth hormone, it does not elevate IGF-1 levels or affect blood glucose, making it safe for those concerned about insulin sensitivity.
Semaglutide's side effects are well-documented and include nausea, vomiting, diarrhea, and constipation, especially during dose titration. Combining the two does not appear to exacerbate these effects. However, researchers should monitor for signs of hypoglycemia if also using insulin or sulfonylureas, though AOD-9604 itself does not lower blood sugar. For menopausal women, the bone-protective potential of AOD-9604 is an area of active investigation, as highlighted in a review of semaglutide fracture data.
How to Reconstitute and Inject AOD-9604
AOD-9604 typically comes as a lyophilized powder in 2 mg or 5 mg vials. To reconstitute, add bacteriostatic water: for a 2 mg vial, adding 2 mL yields a concentration of 1000 mcg/mL, so a 300 mcg dose equals 0.3 mL (30 units on an insulin syringe). For a 5 mg vial, adding 2.5 mL gives 2000 mcg/mL, so 300 mcg is 0.15 mL (15 units). Always use sterile techniques and store reconstituted peptide in the refrigerator.
Inject subcutaneously into fatty tissue, such as the abdomen or thigh, rotating sites to prevent lipodystrophy. Do not inject into muscle or veins. The peptide is fragile; avoid shaking the vial and gently swirl to dissolve. Use within 30 days of reconstitution for optimal potency.
Where to Buy AOD-9604 in Canada for Research
In Canada, AOD-9604 is available for research purposes from specialized peptide vendors. When purchasing AOD-9604 in Canada, look for suppliers that provide third-party purity testing (HPLC or mass spectrometry) and ship domestically to avoid customs delays. Prices for a 5 mg vial typically range from $40 to $80 CAD, depending on the vendor and promotions.
Many researchers buy AOD-9604 online from Canadian peptide companies that cater to the bodybuilding and anti-aging communities. Ensure the product is labeled "for research use only" and not for human consumption. Combining orders with semaglutide from the same source can sometimes reduce shipping costs. For those exploring muscle-sparing strategies, a discussion on AOD-9604 as a muscle-sparing alternative provides context on its role alongside new obesity guidelines.
Frequently Asked Questions About AOD-9604 and Semaglutide Stacking
Can I inject AOD-9604 and semaglutide at the same time?
Yes, but use separate syringes and injection sites. There is no known interaction, but mixing them in the same syringe could compromise peptide stability. Space injections at least 2 inches apart.
Does AOD-9604 cause hunger like other growth hormone peptides?
No, AOD-9604 does not stimulate ghrelin or increase appetite. It is purely lipolytic, so it will not counteract semaglutide's appetite-suppressing effects.
What is the best time of day to take AOD-9604 with semaglutide?
Take AOD-9604 in the morning on an empty stomach. Semaglutide can be injected at any time of day, once weekly, with or without food. Aligning AOD-9604 with your morning routine ensures consistency.
How long until I see results from AOD-9604 and semaglutide?
Semaglutide often shows appetite suppression within days, with weight loss noticeable in 4-8 weeks. AOD-9604's fat-burning effects are more gradual, with visible changes in body composition typically after 8-12 weeks. Patience and consistency are key.
Is AOD-9604 legal in Canada without a prescription?
AOD-9604 is not approved by Health Canada for human use and is sold as a research chemical. It is legal to purchase for research purposes, but not for human consumption. Semaglutide requires a prescription in Canada.
Optimizing Your AOD-9604 and Semaglutide Protocol
To maximize fat loss, combine the peptide stack with a high-protein diet and resistance training. Protein intake of 1.6-2.2 g/kg of body weight helps preserve muscle during the caloric deficit. Even light resistance exercise can enhance the lipolytic effect of AOD-9604 by increasing catecholamine release.
Stay hydrated and monitor electrolyte balance, as semaglutide can cause fluid loss. Some researchers add supplements like omega-3 fatty acids and L-carnitine to support fat oxidation, though these are not required. Track progress with body measurements and DEXA scans if available, as scale weight may not reflect fat loss alone.
For those concerned about bone health during GLP-1 therapy, emerging research suggests AOD-9604 may offer protective effects. A review on semaglutide and bone loss explores this topic in depth, providing valuable insights for researchers.
In summary, an AOD-9604 dosage of 300 mcg daily alongside semaglutide offers a research-backed approach to targeted fat loss in Canada. By following proper reconstitution, injection techniques, and cycling protocols, researchers can safely explore the synergistic potential of these two peptides.